Family-wide Chemical Profiling and Structural Analysis of PARP and Tankyrase Inhibitors

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2012 Feb 21

PMID 22343925

Citations 230

Authors

Elisabet Wahlberg

Tobias Karlberg

Ekaterina Kouznetsova

Natalia Markova

Antonio Macchiarulo

Ann-Gerd Thorsell

Ewa Pol

Asa Frostell

Torun Ekblad

Delal Oncu

Bjorn Kull

Graeme Michael Robertson

Roberto Pellicciari

Herwig Schuler

Johan Weigelt

Affiliations

Soon will be listed here.

Abstract

Inhibitors of poly-ADP-ribose polymerase (PARP) family proteins are currently in clinical trials as cancer therapeutics, yet the specificity of many of these compounds is unknown. Here we evaluated a series of 185 small-molecule inhibitors, including research reagents and compounds being tested clinically, for the ability to bind to the catalytic domains of 13 of the 17 human PARP family members including the tankyrases, TNKS1 and TNKS2. Many of the best-known inhibitors, including TIQ-A, 6(5H)-phenanthridinone, olaparib, ABT-888 and rucaparib, bound to several PARP family members, suggesting that these molecules lack specificity and have promiscuous inhibitory activity. We also determined X-ray crystal structures for five TNKS2 ligand complexes and four PARP14 ligand complexes. In addition to showing that the majority of PARP inhibitors bind multiple targets, these results provide insight into the design of new inhibitors.

Citing Articles

ADP-ribosyltransferase-based biocatalysis of nonhydrolyzable NAD+ analogs.

Sakari M, Bhadane R, Kumar S, Azevedo R, Malakoutikhah M, Masoumi A J Biol Chem. 2024; 301(1):108106.

PMID: 39706271 PMC: 11786771. DOI: 10.1016/j.jbc.2024.108106.

Novel inhibitors of PARP1 and PARP14: design, synthesis, and potentiation of cisplatin efficacy in cancer.

Kam C, Tauber A, Zunk M, McDermott C, Levonis S, Schweiker S Future Med Chem. 2024; 17(1):35-58.

PMID: 39691063 PMC: 11703142. DOI: 10.1080/17568919.2024.2437972.

Role of Exogenous Pyruvate in Maintaining Adenosine Triphosphate Production under High-Glucose Conditions through PARP-Dependent Glycolysis and PARP-Independent Tricarboxylic Acid Cycle.

Yako H, Niimi N, Takaku S, Kato A, Kato K, Sango K Int J Mol Sci. 2024; 25(20).

PMID: 39456870 PMC: 11508270. DOI: 10.3390/ijms252011089.

Tankyrase inhibition promotes endocrine commitment of hPSC-derived pancreatic progenitors.

Poon F, Sambathkumar R, Korytnikov R, Aghazadeh Y, Oakie A, Misra P Nat Commun. 2024; 15(1):8754.

PMID: 39384787 PMC: 11464881. DOI: 10.1038/s41467-024-53068-w.

BRCAness, DNA gaps, and gain and loss of PARP inhibitor-induced synthetic lethality.

Li X, Zou L J Clin Invest. 2024; 134(14).

PMID: 39007266 PMC: 11245158. DOI: 10.1172/JCI181062.

References

Papeo G, Forte B, Orsini P, Perrera C, Posteri H, Scolaro A . Poly(ADP-ribose) polymerase inhibition in cancer therapy: are we close to maturity?. Expert Opin Ther Pat. 2009; 19(10):1377-400. DOI: 10.1517/13543770903215883. View

Hans C, Zerfaoui M, Naura A, Troxclair D, Strong J, Matrougui K . Thieno[2,3-c]isoquinolin-5-one, a potent poly(ADP-ribose) polymerase inhibitor, promotes atherosclerotic plaque regression in high-fat diet-fed apolipoprotein E-deficient mice: effects on inflammatory markers and lipid content. J Pharmacol Exp Ther. 2009; 329(1):150-8. PMC: 2670599. DOI: 10.1124/jpet.108.145938. View

Calabrese C, Almassy R, Barton S, Batey M, Calvert A, Canan-Koch S . Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst. 2004; 96(1):56-67. DOI: 10.1093/jnci/djh005. View

Chiarugi A, Meli E, Calvani M, Picca R, Baronti R, Camaioni E . Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J Pharmacol Exp Ther. 2003; 305(3):943-9. DOI: 10.1124/jpet.103.048934. View

Lehtio L, Jemth A, Collins R, Loseva O, Johansson A, Markova N . Structural basis for inhibitor specificity in human poly(ADP-ribose) polymerase-3. J Med Chem. 2009; 52(9):3108-11. DOI: 10.1021/jm900052j. View

Hassa P, Hottiger M . The diverse biological roles of mammalian PARPS, a small but powerful family of poly-ADP-ribose polymerases. Front Biosci. 2007; 13:3046-82. DOI: 10.2741/2909. View

Sugimura T, Fujimura S, Hasegawa S, Kawamura Y . Polymerization of the adenosine 5'-diphosphate ribose moiety of NAD by rat liver nuclear enzyme. Biochim Biophys Acta. 1967; 138(2):438-41. DOI: 10.1016/0005-2787(67)90507-2. View

Bryant H, Schultz N, Thomas H, Parker K, Flower D, Lopez E . Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature. 2005; 434(7035):913-7. DOI: 10.1038/nature03443. View

Smith S, Giriat I, Schmitt A, de Lange T . Tankyrase, a poly(ADP-ribose) polymerase at human telomeres. Science. 1998; 282(5393):1484-7. DOI: 10.1126/science.282.5393.1484. View

10.

Niesen F, Berglund H, Vedadi M . The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc. 2007; 2(9):2212-21. DOI: 10.1038/nprot.2007.321. View

11.

Fedorov O, Marsden B, Pogacic V, Rellos P, Muller S, Bullock A . A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007; 104(51):20523-8. PMC: 2154464. DOI: 10.1073/pnas.0708800104. View

12.

Karlberg T, Hammarstrom M, Schutz P, Svensson L, Schuler H . Crystal structure of the catalytic domain of human PARP2 in complex with PARP inhibitor ABT-888. Biochemistry. 2010; 49(6):1056-8. DOI: 10.1021/bi902079y. View

13.

Ringner M . What is principal component analysis?. Nat Biotechnol. 2008; 26(3):303-4. DOI: 10.1038/nbt0308-303. View

14.

Iwashita A, Hattori K, Yamamoto H, Ishida J, Kido Y, Kamijo K . Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett. 2005; 579(6):1389-93. DOI: 10.1016/j.febslet.2005.01.036. View

15.

Kauppinen T, Swanson R . The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience. 2006; 145(4):1267-72. DOI: 10.1016/j.neuroscience.2006.09.034. View

16.

Bell C, Eisenberg D . Crystal structure of diphtheria toxin bound to nicotinamide adenine dinucleotide. Biochemistry. 1996; 35(4):1137-49. DOI: 10.1021/bi9520848. View

17.

McCabe N, Cerone M, Ohishi T, Seimiya H, Lord C, Ashworth A . Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene. 2009; 28(11):1465-70. DOI: 10.1038/onc.2008.483. View

18.

Plummer R . Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target. Clin Cancer Res. 2010; 16(18):4527-31. DOI: 10.1158/1078-0432.CCR-10-0984. View

19.

Pellicciari R, Camaioni E, Costantino G, Marinozzi M, Macchiarulo A, Moroni F . Towards new neuroprotective agents: design and synthesis of 4H-thieno[2,3-c] isoquinolin-5-one derivatives as potent PARP-1 inhibitors. Farmaco. 2003; 58(9):851-8. DOI: 10.1016/S0014-827X(03)00143-5. View

20.

Carden C, Yap T, Kaye S . PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol. 2010; 22(5):473-80. DOI: 10.1097/CCO.0b013e32833b5126. View